Abstract
Infection with the hepatitis C virus (HCV) is a worldwide problem. Patients with chronic HCV infection who are non-responders to standard therapy represent a growing population within the HCV epidemic.Novel, more efficient and tolerable therapies are urgently needed. This review discusses the recent results showing that targeting miR-122, a micro-ribonucleic acid (MicroRNA) that enhances HCV replication, is a new anti-HCV therapy with a high barrier to resistance.
Publication Date
11-14-2010
First Page
312
Last Page
317
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Recommended Citation
Said, Elias A.; Canada, Montreal, Quebec,; and Canada., and Montreal
University Hospital Research Center (CR-CHUM), St-Luc Hospital, Montreal, Quebec,
(2010)
"The Need for New Anti-Hepatitis C Virus Therapeutic Strategies : Targeting the cellular micro-ribonucleic acids?,"
Sultan Qaboos University Medical Journal: Vol. 10: 312-317.
DOI: https://doi.org/10.18295/2075-0528.1211
